World-Renowned Pathologist Supports German Company in its Efforts to Lead the Tissue Revolution in Biomedical Research

HAMBURG, Germany, February 4, 2015 /PRNewswire/ --

Former director of the National Cancer Institute's Office of Biorepositories and Biospecimen Research (OBBR), chief medical officer of the National Biomarkers Development Alliance, life sciences professor at Arizona State University, and professor of Laboratory Medicine and Pathology at the Mayo Clinic School of Medicine has agreed to chair the Indivumed GmbH Scientific Advisory Board.

Hartmut Juhl, MD, president, and CEO of Indivumed GmbH, announced today that Carolyn Compton, MD, will lead INDIVUMED's Scientific Advisory Board, advising the company at a critical junction in its history.

When making the announcement, Juhl noted that "INDIVUMED is about to enter a significant growth period in its 12-year history." The former surgical oncologist and cancer researcher went on to say that "the company will strive to expand its current cancer biorepository and clinical data warehouse comprising 20,000 patients to more than 150,000 patients within five years." By all accounts and at today's standards, this would represent the single largest high-quality biorepository for cancer in the world.

"I am thrilled that Carolyn will advise the company for this next stage in our growth," Juhl said. "She has led and continues to lead the tissue revolution in biomedical medical research, as she understands that drug discovery and global development efforts are failing at unprecedented levels in the face of a veritable explosion of cancer cases worldwide."

"We are facing a crisis of confidence in biomedical research in this country. Industry, academia, and the National Cancer Institute are all equally aware that the irreproducibility of research results is crippling our ability to develop new drugs to attack cancer," stated Compton. "Yet the answer to this problem lies right in front of us. INDIVUMED - with its elegant and rigorous approach to the high-quality collection of the most elemental building blocks of molecular medicine, tissues, and associated clinical data - is a crucial part of the answer." Compton went on to characterize Juhl and the company as "pioneers in the field of high-quality tissue collection."

About Indivumed GmbH  

INDIVUMED has established the world's leading high-content tumor database and biobank of the highest quality to support the development of new cancer companion diagnostics and therapies. Alongside the implementation of a highly standardized biospecimen collection process and a unique clinical infrastructure with clinical partners in Germany and the US, INDIVUMED offers a broad range of specialized research services to both biopharmaceutical companies and academia, as well as actively performing a cancer biomarker development program. With its subsidiary IndivuTest GmbH, INDIVUMED provides high-quality tissue-based tumor analysis to patients and has started an initiative with oncologists in Germany and the US to improve personalized cancer therapy strategies in clinical procedures.

For more information, please visit http://www.indivumed.com.

Press contact:
Indivumed GmbH
Swantje Niphut
Marketing Communications Manager
Tel.: +49-40-4133-8375
E-mail: [email protected]
Falkenried 88, Building D
20251 Hamburg
Germany
http://www.indivumed.com

SOURCE Indivumed GmbH